PATENTS

Recent patent applications in noncoding RNAs

Patent number	Description	Assignee	Inventor	Priority application date	Publication date
WO2012106711A3	Determining the structural conformation of a chromosome in a cell, comprising hybridizing target sequences of RNA in the cell with at least one set of fluorescently labeled oligonucleotide probes, where the targeted sequences are transcribed from portions of at least one chromosome, and where the pattern of fluorescently labeled probes hybridized to the target sequences indicates the structural conformation of the chromosome.	Trustees of the University of Pennsylvania (Philadelphia), Raj A, Levesque MJ	Raj A, Levesque MJ	2/4/2011	3/13/2014
US20140066323A1	A method of diagnosing, prognosing, determining progression of a cancer or predicting benefit from therapy in a subject, comprising assaying an expression level in a sample from the subject for a plurality of targets.	Mayo Foundation for Medical Education & Research (Rochester, MN, USA), GenomeDx Biosciences (Vancouver, BC, Canada)	Buerki C, Crisan A, Davicioni E, Erho NG, Ghadessi M, Jenkins RB, Vergara Correa IA	8/16/2012	3/6/2014
US20140065616A1	A method to screen, isolate and assay a region of interest in chromosomal cellular chromatin cells, comprising obtaining the target sequence of the region of interest in chromosomal cellular chromatin and/or a genomic library clone that contains the region of interest; determining the target sequence structure and potential binding sites of associated factors; modifying the target sequence by selecting and/or introducing at least one unique sequence or binding site that can be used to select the target sequence, and monitoring the target sequence status.	Xu H	Xu H	9/6/2012	3/6/2014
US20140056929A1	Compositions and methods of modulating an immune response by controlling levels of IFN-γ production by leukocytes. Adjustment of IFN-γ levels is achieved by increasing or decreasing the activity of NeST (nettoie Salmonella pas Theiler's [cleanup Salmonella not Theiler's]), a long noncoding RNA that induces expression of IFN-γ.	The Stanford University Board of Trustees (Palo Alto, CA, USA)	Kirkegaard KA, Brahic M, Gomez JA, Chang HYH	8/23/2012	2/27/2014
US20140045915A1	A method of assaying a biological sample from a subject in aid of diagnosis, prognosis or monitoring of a disease or other medical condition, comprising obtaining or using a microvesicle fraction from a biological sample from a subject; extracting nucleic acid from the fraction; and detecting the presence or absence of a biomarker in the extracted nucleic acid, where the biomarker is a genetic aberration associated with diagnosis, prognosis, status or stage of a disease or other medical condition.	General Hospital Corp. (Boston), Skog JKO, Balaj L, Noerholm M, Breakefield XO	Skog JKO, Balaj L, Noerholm M, Breakefield XO	8/31/2010	2/13/2014
EP2695947A1	A method of producing a recombinant polypeptide, and more specifically, to a method of producing a polypeptide efficiently using an animal cell in which the expression of nuclear factor κB inhibitor α (NfkBia) has been decreased.	Chugai Seiyaku Kabushiki Kaisha (Tokyo)	Tabuchi H, Sugiyama T	4/1/2011	2/12/2014
US8628923B2	Methods useful for analyzing the genomic DNA or RNA (e.g., noncoding RNA or mRNA) of small populations of cells or single cells, comprising performing whole genome amplification of the genome of a single cell to produce an amplified genome; pre-amplifying the amplified genome to produce a pre-amplification reaction mixture comprising amplicons specific for target nucleic acids; and amplifying and detecting the amplicons.	Fluidigm (S. San Francisco, CA, USA), Hamilton A, Lin M, Mir A, Pieprzyk M	Hamilton A, Lin M, Mir A, Pieprzyk M	1/13/2009	1/14/2014
WO2013188037A2	Processing a target RNA, comprising contacting the products of an RNA ligase-mediated ligation reaction with a CAS6 protein, where the RNA ligase-mediated ligation reaction comprises a target RNA, an RNA ligase, and first and second adaptors that can ligate together to produce an adaptor dimer that contains a CRISPR stem loop; the CAS6 protein recognizes the CRISPR stem loop, thus preventing the adaptor dimer from being reverse transcribed.	Agilent Technologies (Santa Clara, CA, USA)	Zeiner G, Bruhn L	6/11/2012	12/19/2013
EP2673363A2	Inhibiting endothelial recruitment in a subject, involving administering to the subject a first agent that inhibits expression or activity of a first protein selected from insulin-like growth factor binding protein-2 (IGFBP2), c-mer proto-oncogene tyrosine kinase (MERTK), and phosphatidylinositol transfer protein, cytoplasmic 1 (PITPNC1) or a first agent that increases expression or activity of growth arrest specific 6 (GAS6).	The Rockefeller University (New York)	Tavazoie S, Halberg N, Png K	2/11/2011	12/18/2013
US20130331275A1	Detecting an RNA molecule in a sample, comprising combining the sample with at least one first adaptor, at least one second adaptor, and a polypeptide comprising double-strand–specific RNA ligase activity to form a ligation reaction composition.	Applied Biosystems (Carlsbad, CA, USA)	Kuersten RS	1/14/2008	12/12/2013

Source: Thomson Scientific Search Service. The status of each application is slightly different from country to country. For further details, contact Thomson Reuters (Search Service), 1925 Ballenger Avenue, Suite 400, Alexandria, VA 22314, USA. Tel: 1 (800) 337-9368 (http://thomsonreuters.com/).